Iron replacement therapy in cancer-related anemia

American Journal of Health-System Pharmacy

Volumn 68, Issue 10 SUPPL. 1, 2011, Pages

  BariBeault, DaviD ^a   AuerBach, Michael ^b,c  

^a BOSTON MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Anemia; Blood; Drug administration; Hematopoietic agents; Injections; Iron preparations; National comprehensive cancer network; Neoplasms; Protocols; Toxicity

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ANEMIA; BLOOD TRANSFUSION; CANCER RELATED ANEMIA; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATION; IRON DEFICIENCY; IRON THERAPY; MYALGIA; NAUSEA; NUTRITIONAL DEFICIENCY; PAIN; PATHOPHYSIOLOGY; PERIORBITAL EDEMA; PRIORITY JOURNAL; PRURITUS; STRIDOR; TACHYCARDIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; VOMITING; WHEEZING;

EID: 79957848250     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110039     Document Type: Conference Paper

References (60)

1. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116(suppl 7A):11S-26S.
2. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health-Syst Pharm. 2007; 64(suppl 2):S5-13.
3. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91:1616-34. (Pubitemid 29479929)
4. World Health Organization, Centers for Disease Control and Prevention. Worldwide prevalence of anaemia 1993-2005: WHO Global Database on Anaemia. http://whqlibdoc.who.int/publications/2008/9789241596657-eng.pdf (accessed 2010 Aug 16).
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer- and chemotherapy-induced anemia, version 1.2011. www.nccn.org/professionals/physician-gls/f-guidelines.asp (accessed 2011 Mar 28).
6. Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol. 2008; 25:12-21.
7. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and longterm outcome. Oncology. 2005; 69(suppl 2):2-7. (Pubitemid 41507248)
8. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000; 5:353-60.
9. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol. 1994; 21:3-8. (Pubitemid 24172363)
10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352:1011-23.
11. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007; 369:1502-4. (Pubitemid 46670290)
12. Henry DH, Dahl NV. Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy. Commun Oncol. 2007; 4:95-101.
13. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hema tology Am Soc Hematol Educ Program. 2006:29-35.
14. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998; 25:43-6. (Pubitemid 28326224)
15. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol. 2008; 83:580-8. (Pubitemid 351874877)
16. Feelders RA, Vreugdenhil G, Eggermont AM et al. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest. 1998; 28:520-7. (Pubitemid 28350015)
17. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004; 22:1301-7. (Pubitemid 41079845)
18. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997; 15:1218-34. (Pubitemid 27106310)
19. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998; 16:3412-25. (Pubitemid 28481641)
20. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19:2875-82. (Pubitemid 32538197)
21. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19:2865-74. (Pubitemid 32538196)
22. Auerbach M, Ballard H. Intravenous iron in oncology. J Natl Compr Canc Netw. 2008; 6:585-92. (Pubitemid 352007766)
23. Pedrazzoli P, Farris A, Del PS et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008; 26:1619-25.
24. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008; 26:1611-8.
25. Markowitz GS, Kahn GA, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol. 1997; 48:34-40. (Pubitemid 27312084)
26. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50:1694-9. (Pubitemid 26364277)
27. Feraheme (ferumoxytol injection for intravenous use) prescribing information. Lexington, MA: AMAG Pharmaceuticals; 2009.
28. Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion. 2010; 50:719-32.
29. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316:73-8. (Pubitemid 17052741)
30. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995; 26:41-6.
31. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(suppl 3):S1-145.
32. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12:231-42.
33. Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007; 21:627-32. (Pubitemid 46444544)
34. Auerbach M, Silberstein PT, Webb RT et al. Darbepoetin alfa 300 or 500 mg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010; 85:655-63.
35. Steensma DP, Sloan JA, Dakhil SR et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011; 29:97-105.
36. Shord SS, Cuellar S. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation. J Am Pharm Assoc. 2008; 48:487-93.
37. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980; 243:1726-31. (Pubitemid 10148807)
38. Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002; 61:1830-9. (Pubitemid 34437938)
39. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003; 63:217-24. (Pubitemid 35463924)
40. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999; 33:464-70.
41. Chertow GM, Mason PD, Vaage-Nilsen O et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21:378-82. (Pubitemid 43159991)
42. Chertow GM, Mason PD, Vaage-Nilsen O et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004; 19:1571-5. (Pubitemid 38796422)
43. Wysowski DK, Swartz L, Borders-Hemphill BV et al. Use of parenteral iron products and serious anaphylactictype reactions. Am J Hematol. 2010; 85:650-4.
44. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfus Altern Transfus Med. 2007; 9:8-36.
45. Sav T, Tokgoz B, Sipahioglu MH et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007; 29:423-6. (Pubitemid 46752324)
46. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med. 2007; 9:42.
47. Prakash S, Walele A, Dimkovic N et al. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int. 2001; 21:290-5. (Pubitemid 32734437)
48. Barton JC, Barton EH, Bertoli LF et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000; 109:27-32. (Pubitemid 30608734)
49. Auerbach M, Ballard H. Intravenous iron as standard of care in oncology: opportunity lost. J Am Pharm Assoc. 2008; 48:455-7.
50. Collins A. Trend in iron testing and IV iron dosing in cancer patients receiving chemotherapy and ESA versus dialysis patients. Paper presented at American Society of Hematology 45th Annual Meeting. San Diego, CA; 2003 Dec.
51. Glaspy JA. The development of erythropoietic agents in oncology. Expert Opin Emerg Drugs. 2005; 10:553-67. (Pubitemid 41176287)
52. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007; 50:476-530.
53. Centers for Medicare and Medicaid Services. Decision memo for erythropoiesis stimulating agents (ESAs) for nonrenal disease indications (CAG-00383N) www.cms.gov/determinationprocess/downloads/id203d.pdf (accessed 2011 Apr 8).
54. Vekeman F, Bookhart BK, White J et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion. 2009; 49:895-902.
55. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004; 44:866-76. (Pubitemid 39445919)
56. Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy. 2010; 30:70-9.
57. Provenzano R, Schiller B, Rao M et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4:386-93.
58. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19:1599-605.
59. AMAG Pharmaceut icals. AMAG Pharmaceuticals announces update to Feraheme label. http://ir.amagpharmaceuticals.com/phoenix.zhtml?c=61596&p= irolnewsArticle&ID=1500531&highlight= (accessed 2011 Apr 11).
60. MonoFer (iron isomaltoside 1000) summary of product characteristics. Holbaek, Denmark: Pharmacosmos A/S; 2010.